Literature DB >> 26762471

Chinese SLE Treatment and Research group (CSTAR) registry VII: prevalence and clinical significance of serositis in Chinese patients with systemic lupus erythematosus.

J Zhao1, W Bai1, P Zhu2, X Zhang3, S Liu4, L Wu5, L Ma6, L Bi7, X Zuo8, L Sun9, C Huang10, X Tian1, M Li1, Y Zhao1, X Zeng1.   

Abstract

OBJECTIVES: To investigate both the prevalence and clinical characteristics of serositis in Chinese patients with systemic lupus erythematosus (SLE) in a large cohort in the Chinese SLE Treatment and Research group (CSTAR) database.
METHODS: A prospective cross-sectional study of patients with SLE was conducted based on the data from the CSTAR registry. Serositis was defined according to the 1999 revised American College of Rheumatology (ACR) criteria for SLE - that is, pleuritis/pleural effusion and/or pericarditis/pericardial effusion detected by echocardiography, chest X-ray or chest computerized tomography (CT) scan. Peritonitis/peritoneal effusion were confirmed by abdominal ultrasonography. We analysed the prevalence and clinical associations of serositis with demographic data, organ involvements, laboratory findings and SLE disease activity.
RESULTS: Of 2104 patients with SLE, 345 were diagnosed with serositis. The prevalence of lupus nephritis (LN), interstitial lung disease and pulmonary arterial hypertension, as well as the presence of leukocytopenia, thrombocytopenia, hypocomplementemia and anti-dsDNA antibodies was significantly higher in patients with serositis (P < 0.05). Significantly higher SLE disease activity scores were found in patients with serositis compared to those patients without serositis (P < 0.05). Lupus-related peritonitis had similar clinical manifestations and laboratory profiles as serositis caused by SLE.
CONCLUSIONS: There is a significant association of nephropathy, interstitial lung disease, pulmonary arterial hypertension, hypocomplementemia, leukocytopenia, thrombocytopenia and elevated anti-dsDNA antibodies with serositis. The results suggest that higher SLE disease activity contributes to serositis development, and should be treated aggressively.
© The Author(s) 2016.

Entities:  

Keywords:  Prevalence; clinical significance; serositis; systemic lupus erythematosus

Mesh:

Year:  2016        PMID: 26762471     DOI: 10.1177/0961203315625460

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  16 in total

Review 1.  Successful treatment of systemic lupus erythematosus pleuropericarditis with belimumab.

Authors:  Irene Carrión-Barberà; Tarek Carlos Salman-Monte; Sonia Castell; Francisco Castro-Domínguez; Fabiola Ojeda; Jordi Monfort
Journal:  Eur J Rheumatol       Date:  2019-05-20

2.  Features associated with pulmonary arterial hypertension in Chinese hospitalized systemic lupus erythematosus patients.

Authors:  Shu-Zhen Xu; Xiang-Pei Li; Xiao-Mei Li; Zong-Wen Shuai; Rui-Xue Leng; Hai-Feng Pan; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2018-03-08       Impact factor: 2.980

3.  The prevalence and risk factors for serositis in patients with systemic lupus erythematosus: a cross-sectional study.

Authors:  Yan Liang; Rui-Xue Leng; Hai-Feng Pan; Dong-Qing Ye
Journal:  Rheumatol Int       Date:  2016-12-20       Impact factor: 2.631

4.  The role of anti-ribosomal P autoantibodies in the prediction of neuropsychiatric damage in systemic lupus erythematosus based on CSTAR cohort (XIV).

Authors:  Yufang Ding; Jiuliang Zhao; Junyan Qian; Li Zhang; Shangzhu Zhang; Nan Jiang; Jing Li; Chanyuan Wu; Qingjun Wu; Dong Xu; Xiaomei Leng; Qian Wang; Wen Zhang; Xinping Tian; Mengtao Li; Xiaofeng Zeng
Journal:  Clin Rheumatol       Date:  2022-01-27       Impact factor: 2.980

5.  Refractory chylous pleural effusion with systemic lupus erythematosus : Surgical treatment when steroid/immunosuppressant resistant.

Authors:  Peng Song; JingCheng Zhang; CongCong Shang; Li Zhang
Journal:  Z Rheumatol       Date:  2019-10       Impact factor: 1.372

Review 6.  An Update for Mesenchymal Stem Cell Therapy in Lupus Nephritis.

Authors:  Wenchao Li; Weiwei Chen; Lingyun Sun
Journal:  Kidney Dis (Basel)       Date:  2021-02-19

7.  Relationship between hyperuricemia and serositis in patients with lupus nephritis.

Authors:  Ping Nie; Liangqian Hu; Bing Li; Yan Lou; Manyu Luo; Yali Wang; Xuehong Lu; Ping Luo
Journal:  Int Urol Nephrol       Date:  2021-05-10       Impact factor: 2.370

8.  Risk factors for the flare of systemic lupus erythematosus and its influence on prognosis: a single-center retrospective analysis.

Authors:  Xiaohong Zeng; Ling Zheng; Hongbing Rui; Rihui Kang; Junmin Chen; Huaning Chen; Jizan Liu
Journal:  Adv Rheumatol       Date:  2021-07-02

9.  CircELK4 Contributes to Lupus Nephritis by Acting as a miR-27b-3p Sponge to Regulate STING/IRF3/IFN-I Signaling.

Authors:  Zhi-Quan Xu; Yan Ding; Xiao-Yan Huang; Wei Xiang; Xiao-Jie He
Journal:  Inflammation       Date:  2021-06-05       Impact factor: 4.092

Review 10.  Lupus Cohorts.

Authors:  Christopher Redmond; Omer Pamuk; Sarfaraz A Hasni
Journal:  Rheum Dis Clin North Am       Date:  2021-06-10       Impact factor: 2.032

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.